Skip to content

Study · Case report or series · n = 18 · 2025

5 results

Hypertrichosis associated with the use of C-type natriuretic peptide analogue: a case report.

Clinton JL Jr, Magalhaes TSPC, Bordallo AP, Collett-Solberg PF

Journal of medical case reports22 Apr 2025Cited by 2 (Europe PMC)

PMID40264232 (opens in a new tab)PMCIDPMC12016056 (opens in a new tab)DOI10.1186/s13256-025-05231-0 (opens in a new tab)PepBankPUB-40264232
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In children with achondroplasia receiving vosoritide, 11 of 18 developed hypertrichosis, including 8 girls and 3 boys.

    In plain wordsIn children with achondroplasia receiving vosoritide, 11 of 18 developed excess hair growth.

    Peptide
    Vosoritide
    Outcome
    Not applicableHypertrichosis
    Study

    n = 18

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · subcutaneous · at least 3 monthsAs given in this study (human).

    Measurements

    Patients with hypertrichosis
    11 patients
    of 18 patients receiving subcutaneous vosoritide
    Proportion with hypertrichosis
    61.1%
    of 18 patients
    Girls with hypertrichosis
    8 girls
    of 11 girls
    Boys with hypertrichosis
    3 boys
    of 7 boys

    Source sentences

    Summary
    Out of 18 patients (11 girls and 7 boys) ranging in age from 2 to 10 years, 11 developed hypertrichosis (8 girls and 3 boys).
    3 context sentences
    Summary · context
    Out of the 18 patients (61.1%) receiving regular subcutaneous vosoritide, 11 developed hypertrichosis, characterized by pigmented, thin, and short hair on the face, arms, abdomen, back, and legs.
    Summary · context
    This is a case report highlighting an atypical adverse event in a group of patients with achondroplasia using vosoritide for at least 3 months.
    Summary · context
    The study included a total of 18 patients, all of whom were from Brazil.
  2. 02HumanCase report or seriesSafety outcome

    In children with achondroplasia receiving vosoritide, no patients showed virilization.

    In plain wordsNo children receiving vosoritide showed virilization.

    Peptide
    Vosoritide
    Outcome
    Not applicableVirilization
    Study

    n = 18

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · at least 3 monthsAs given in this study (human).

    Source sentences

    Summary
    None of the patients exhibited signs of virilization, advanced bone age, or elevated androgen levels.
    2 context sentences
    Summary · context
    This is a case report highlighting an atypical adverse event in a group of patients with achondroplasia using vosoritide for at least 3 months.
    Summary · context
    The study included a total of 18 patients, all of whom were from Brazil.
  3. 03HumanCase report or seriesSafety outcome

    In children with achondroplasia receiving vosoritide, no patients showed advanced bone age.

    In plain wordsNo children receiving vosoritide showed advanced bone age.

    Peptide
    Vosoritide
    Outcome
    Not applicableAdvanced bone age
    Study

    n = 18

    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · at least 3 monthsAs given in this study (human).

    Source sentences

    Summary
    None of the patients exhibited signs of virilization, advanced bone age, or elevated androgen levels.
    2 context sentences
    Summary · context
    This is a case report highlighting an atypical adverse event in a group of patients with achondroplasia using vosoritide for at least 3 months.
    Summary · context
    The study included a total of 18 patients, all of whom were from Brazil.
  4. 04HumanCase report or seriesSafety outcome

    In children with achondroplasia receiving vosoritide, no patients showed elevated androgen levels.

    In plain wordsNo children receiving vosoritide showed elevated androgen levels.

    Peptide
    Vosoritide
    Outcome
    Not applicableElevated androgen levels
    Study

    n = 18

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · at least 3 monthsAs given in this study (human).

    Source sentences

    Summary
    None of the patients exhibited signs of virilization, advanced bone age, or elevated androgen levels.
    2 context sentences
    Summary · context
    This is a case report highlighting an atypical adverse event in a group of patients with achondroplasia using vosoritide for at least 3 months.
    Summary · context
    The study included a total of 18 patients, all of whom were from Brazil.
  5. 05HumanCase report or seriesSafety outcome

    In children with achondroplasia, hypertrichosis resolved after vosoritide discontinuation.

    In plain wordsIn children with achondroplasia, excess hair growth resolved after vosoritide stopped.

    Peptide
    Vosoritide
    Outcome
    DecreaseHypertrichosis after discontinuation
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · subcutaneous · at least 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The hypertrichosis resolved after discontinuation of treatment.
    2 context sentences
    Summary · context
    This is a case report highlighting an atypical adverse event in a group of patients with achondroplasia using vosoritide for at least 3 months.
    Summary · context
    The study included a total of 18 patients, all of whom were from Brazil.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.